Incretin and KATP Channels

NCT01934816 · Terminated

Last updated 2026-05-28

This clinical trial tests how incretin hormones and KATP channels affect skin blood flow in healthy individuals.

Status Terminated Stopped early and will not restart.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind health-services study

Participants 2 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2013-06 · est. completion 2015-10

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT01934816 ↗

Description as written by the study sponsor.

This study aims to examine the involvement of KATP channels on the microvascular actions of the incretin GLP-1 and its analogues in healthy individuals and to determine whether the acute oral administration of different KATP channel blockers which are oral medications for Type 2 diabetes such as Glibenclamide and Glimepiride differentially modulate the microvascular responses in these individuals.

Treatments tested

Intradermal injections of GLP-1 and its analogues also known as microinjection of GLP-1 (native GLP-1), and its analogues such as Exenatide(Byetta), and Liraglutide (Victoza) Other

native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms

Main thing measured	Change in skin blood flow to GLP-1 and its analogues
Sponsor	Katarina Kos
Conditions studied	Healthy Subjects
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01934816 ↗